Psilocybin
Medicinal Psilocybin Dispensaries Have Started Popping Up Across Canada
Activism on drug decriminalization and emerging scientific evidence on the potential benefits of psychedelic substances are raising questions about the validity of a blanket prohibition of Psylocybin…

This article was originally published by Truffle Report.

What is Driving the Expansion of the Psilocybin Grey Market?
Advocacy around psychedelics, and particularly the push toward medicalization of psilocybin mushrooms, has been growing stronger for the last three years. As 2021 marked the fifth year of the opioid overdose emergency in British Columbia, activists were seen distributing samples of clean drugs, including heroin and meth, as a act of protest against the existing drug laws. Larsen was one of them. Meanwhile, British Columbia has also put forward a request asking the federal government for a province-wide exemption from criminal penalties for drug possession while Vancouver stands to become the first city in Canada to decriminalize possession of drugs. A positive response to dispensary products at the ground level has been contributing to the growth of Larsen’s psilocybin sales. “A few months ago after we opened the storefront to expand access, we had such a positive response to the microdosing. Not a single negative reaction or anybody having a problem,” Larsen says. “We decided to start offering stronger dosages, restricted by medical need,” he says, responding to the success of storefront services. Larsen has moved from only selling microdoses of psilocybin to higher doses with dried mushrooms and mushrooms in chocolates. He says that requirements to access the products remain the same. “We will provide microdoses to any adult over the age of 19 who promises to use them responsibly. The stronger products, the whole mushrooms and the mushroom chocolates, require some kind of medical diagnosis,” Larsen says. However, selling larger doses is not without its own concerns, and he adds, “What I worry about is somebody’s not following our guidelines, being irresponsible in some way, and then hurting themselves or hurting someone else and that reflecting poorly on us.” Psilocybin mushrooms are developing a reputation for efficacy in treating substance abuse disorders. A 2017 study published by Global Drug Survey claimed mushrooms to be “one of the safest drugs in the world”. Larsen shared that he has a client base of at least 4,000 individuals at the moment, including some who sought mushrooms for their legally exempted psychedelic-assisted therapy. This has doubled since we last spoke, when he told Truffle Report that he was providing psychedelic medicines to about 2000 Canadians. However, the consumption pattern for psilocybin is different from cannabis use. “There’s less demand for mushrooms and there is for cannabis overall,” Larsen says. Any cannabis user might consume cannabis multiple times a day but even a heavy mushroom user wouldn’t dose more than once or twice a week. “Even that will be considered a lot. I think microdosing of substance will be something that’ll expand the most,” he says. Larsen has also started to deal with other substances that are “actually more legal than the mushrooms”, including microdoses of 1P-LSD. The growing market and demand, however, shows that while the federal government is still debating the decriminalization of substances, Canadians have chosen not to wait. “I also want to see others joining in this movement. I don’t think I’m going to be able to monopolize the mushroom trade in Canada any more than I monopolized the marijuana trade,” Larsen says. The post Canada’s Expanding Psilocybin Grey Market appeared first on Truffle Report. psilocybin mushroom lsd psychedelic microdosing therapy medicinal mushroom psychedelics trading laws decriminalization controlled drugs and substances act legalization
Continue Reading
-
MDMA22 hours ago
Shifting Strategy, MAPS Turns to Equity Investment
-
Public Companies10 hours ago
Atai CEO Answers Questions From the Public
-
Psilocybin8 hours ago
PSYC’s CEO to Moderate Panel at Film Screening for ESPN’s Upcoming Documentary, “Peace of Mind”
-
Public Companies6 hours ago
PharmaTher Announces Positive FDA Meeting; Path Towards Phase 3 Trial
-
MDMA5 hours ago
Massachusetts Republican Wants to Cap Potential MDMA Therapy Costs
-
Psilocybin3 hours ago
Psilocybin Therapies Attract Support in Illinois Legislature
-
Psychedelics2 hours ago
Joël Brierre Calls To Those Seeking Transformation – Podcast Episode #24